NCT01968460 is a twelve-week multi-Center, randomized, double-blind, placebo-controlled, parallel group study, to determine the safety, tolerability and efficacy of two doses of once daily P2B001 in subjects with early Parkinson's Disease.
|This item is relevant to you: Parkinson's disease||1||0||
- Can't tell
What people switch to and from
Patients started using Parkinson's Phase 2B Study Pramipexole / Rasagiline Mesylate after stopping:
|This item is relevant to you: Rasagiline (Azilect)||1||